[1] 中华医学会心血管病学分会介入心脏病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南(2016)[J]. 中华心血管病杂志, 2016, 44(5):382-400. [2] 中华医学会心血管病学分会. 抗血小板药物治疗反应多样性临床检测和处理的中国专家建议[J].中华心血管病杂志,2014,42(12):986-991. [3] 曾秋棠, 彭昱东. 急性冠脉综合征和冠脉支架患者的抗血小板优化治疗[J]. 临床心血管病杂志, 2017, 33(6):570-575. [4] 陈逸伦, 李晶晶, 耿晓雯, 等. 氯吡格雷对冠心病合并慢肾病患者抑制血小板聚集作用的影响[J].中国循环杂志, 2015,30(7):647-649. [5] 杨宝峰. 药理学[M]. 7版.北京:人民卫生出版社, 2008: 184. [6] Varenhorst C,James S, Erlinge D, et al.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamics responses to clopidogrel but not prasugrel in aspirin‐treated patients with coronary artery disease[J]. European Heart Journal, 2009(30):1744-1752. [7] Bhindi R, Ormerod O, Newton J, et, al. Interaction between statins and clopidogrel: is there anything clinically relevant?[J] Monthly Journal of the Association of Physicians,2008(101): 915-925. [8] Ganesan S, Williams C, Maslen CL,et al.Clopidogrel variability: role of plasma protein binding alterations[J]. British Journal of Clinical Pharmacology, 2013, 75(6):1468. [9] Lennern s H. Clinical Pharmacokinetics of Atorvastatin[J]. Clinical Pharmacokinetics, 2003, 42(13) :1141-1160. [10] 林鑫,郭进京,任慧玲.基于WHOART的我国心血管系统药物致不良反应病例报告分析[J].中国药物警戒,2019,16(3):157-163. [11] Mangoni AA, Jackson SHD.Age-related changes in pharmacokinetics and pharmacodynamics : basic principles and practical applications[J]. British Journal of Clinical Pharmacology, 2015,57(1):6-14. [12] 李志诚. 一例冠状动脉介入术后合并肺栓塞应用抗栓药致消化道出血的药学监护[J].中国药物警戒,2018,15(5):308-311. [13] 华参,李田昌,王宇彬,等. CRUSADE评分、HAS-BLED评分预测心房颤动并PCI患者院内及远期出血风险的比较[J]. 临床心血管病杂志,2017,33(6):570-575. [14] ACS-PCI患者肾功能状态调查协作组.急性冠状动脉综合征接受介入治疗患者肾功能状态多中心注册研究[J].北京大学学报(医学版),2007, 39(6):624-629. |